Online inquiry

IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2870MR)

This product GTTS-WQ2870MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CCR4 gene. The antibody can be applied in Tropical spastic paraparesis, Adult T cell leukemia/lymphoma (ATL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005508.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1233
UniProt ID P51679
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2870MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3961MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ594MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ10751MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ8432MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ10295MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ14009MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ4187MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ9963MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KBSA301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW